Cost-effectiveness analysis of molecular testing in minimally invasive samples to detect endometrial cancer in women with postmenopausal bleeding.
Paula Peremiquel-TrillasDavid GómezJosé Manuel MartínezSergi Fernández-GonzálezJon Frias-GomezSonia PaytubiBeatriz PelegrinaMarta PinedaJoan BrunetJordi PonceXavier Matias-GuiuXavier BoschSilvia de SanjoséLaia BruniLaia AlemanyLaura CostasMireia DíazPublished in: British journal of cancer (2023)
The introduction of molecular testing to diagnose endometrial cancer in women presenting postmenopausal bleeding provides more health benefit at a lower cost, and therefore has the potential to be cost-effective.